{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.19","pValueComment":"The reported p-value is representative of the changes in levels of IFNƴ among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.72","pValueComment":"The reported p-value is representative of the changes in levels of IFNƴ among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.03","pValueComment":"The reported p-value is representative of the changes in levels of IFNƴ among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The reported p-value is representative of the changes in levels of IL4 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The reported p-value is representative of the changes in levels of IL4 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The reported p-value is representative of the changes in levels of IL4 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.005","pValueComment":"The reported p-value is representative of the changes in levels of IL6 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.06","pValueComment":"The reported p-value is representative of the changes in levels of IL6 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.007","pValueComment":"The reported p-value is representative of the changes in levels of IL6 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.0003","pValueComment":"The reported p-value is representative of the changes in levels of IL8 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.0002","pValueComment":"The reported p-value is representative of the changes in levels of IL8 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.01","pValueComment":"The reported p-value is representative of the changes in levels of IL8 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.03","pValueComment":"The reported p-value is representative of the changes in levels of IL6 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.91","pValueComment":"The reported p-value is representative of the changes in levels of IL10 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.64","pValueComment":"The reported p-value is representative of the changes in levels of IL10 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.70","pValueComment":"The reported p-value is representative of the changes in levels of IL12 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.59","pValueComment":"The reported p-value is representative of the changes in levels of IL12 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.26","pValueComment":"The reported p-value is representative of the changes in levels of IL12 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.0008","pValueComment":"The reported p-value is representative of the changes in levels of IL13 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The reported p-value is representative of the changes in levels of IL13 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.007","pValueComment":"The reported p-value is representative of the changes in levels of IL13 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.005","pValueComment":"The reported p-value is representative of the changes in levels of TNFα among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.007","pValueComment":"The reported p-value is representative of the changes in levels of TNFα among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.007","pValueComment":"The reported p-value is representative of the changes in levels of TNFα among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.42","pValueComment":"The reported p-value is representative of the changes in levels of IP-10 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.85","pValueComment":"The reported p-value is representative of the changes in levels of IP-10 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.16","pValueComment":"The reported p-value is representative of the changes in levels of IP-10 among all participants. Two tailed Wilcoxon signed rank test without adjustment for multiple comparisons.","statisticalMethod":"Wilcoxon signed rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.7","upperLimit":"1.4","value":"-0.3"},{"groupId":"OG001","lowerLimit":"-7.4","upperLimit":"4.5","value":"-0.4"},{"groupId":"OG002","lowerLimit":"-5.3","upperLimit":"55.1","value":"-2.4"}]}],"title":"Interferon gamma (ƴ)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.1","value":"0.07"},{"groupId":"OG001","lowerLimit":"0.04","upperLimit":"0.2","value":"0.1"},{"groupId":"OG002","lowerLimit":"0.001","upperLimit":"0.1","value":"0.06"}]}],"title":"Interleukin 4 (IL4)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.04","upperLimit":"1.8","value":"0.4"},{"groupId":"OG001","lowerLimit":"-0.3","upperLimit":"1.1","value":"0.3"},{"groupId":"OG002","lowerLimit":"-0.3","upperLimit":"5.8","value":"0.6"}]}],"title":"Interleukin 6 (IL6)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"163.1","value":"71.9"},{"groupId":"OG001","lowerLimit":"-0.2","upperLimit":"233.1","value":"64.8"},{"groupId":"OG002","lowerLimit":"-9.1","upperLimit":"121.1","value":"47.5"}]}],"title":"Interleukin 8 (IL8)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.1","upperLimit":"1.4","value":"0.1"},{"groupId":"OG001","lowerLimit":"-0.2","upperLimit":"0.4","value":"-0.03"},{"groupId":"OG002","lowerLimit":"-0.3","upperLimit":"0.2","value":"-0.05"}]}],"title":"Interleukin 10 (IL10)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.08","upperLimit":"0.09","value":"0.02"},{"groupId":"OG001","lowerLimit":"-0.07","upperLimit":"0.09","value":"0.00"},{"groupId":"OG002","lowerLimit":"-0.07","upperLimit":"0.14","value":"0.03"}]}],"title":"Interleukin 12 (IL12)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"1.9","value":"0.7"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"1.7","value":"0.9"},{"groupId":"OG002","lowerLimit":"-0.02","upperLimit":"1.3","value":"0.6"}]}],"title":"Interleukin 13 (IL13)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.09","upperLimit":"0.8","value":"0.3"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"0.8","value":"0.5"},{"groupId":"OG002","lowerLimit":"-0.3","upperLimit":"0.4","value":"0.06"}]}],"title":"Tumor necrosis factor alpha (TNFα)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-214.5","upperLimit":"239.3","value":"76.5"},{"groupId":"OG001","lowerLimit":"-271.7","upperLimit":"216.6","value":"18.4"},{"groupId":"OG002","lowerLimit":"-335.7","upperLimit":"127.8","value":"-73.3"}]}],"title":"Interferon (IFN)-inducible protein 10 (IP-10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Cytokines were evaluated using MSD 96-Well Multiarray Proinflammatory 7-plex assay (MesoScale Discovery).","dispersionType":"Inter-Quartile Range","groups":[{"description":"Baseline to 4 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"Baseline to 4 Weeks"},{"description":"Baseline to 8 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG001","title":"Baseline to 8 Weeks"},{"description":"Baseline to end of treatment for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG002","title":"Baseline to End of Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to 4 weeks, baseline to 8 weeks and baseline to end of treatment","title":"Change in Cytokines From Baseline to 4 Weeks, Baseline to 8 Weeks and End of Treatment","type":"SECONDARY","unitOfMeasure":"pg/mL"}